行情

CRVS

CRVS

Corvus Pharms
NASDAQ

实时行情|Nasdaq Last Sale

3.560
+0.030
+0.85%
休市 16:00 09/20 EDT
开盘
3.530
昨收
3.530
最高
3.640
最低
3.510
成交量
11.19万
成交额
--
52周最高
10.04
52周最低
3.200
市值
1.04亿
市盈率(TTM)
-2.2826
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

CRVS 新闻

  • 欧洲最大骗税案开审 "掠夺欧洲的男人"出庭披露内幕
  • 新京报.1小时前
  • 2025年或推出AR眼镜 Facebook能否扭转行业颓势?
  • 新浪财经-自媒体综合.2小时前
  • 据悉任天堂千方百计将Switch Lite售价压低至200美元
  • 新浪财经综合.3小时前
  • 猪瘟扩散 日本政府决定为生猪接种疫苗
  • 央视.4小时前

更多

所属板块

生物技术和医学研究
+0.62%
制药与医学研究
+0.95%

热门股票

名称
价格
涨跌幅

CRVS 简况

Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapies. The Company is developing drugs and antibodies that block crucial immune checkpoints and reprogram immune T-cells. The Company has a pipeline of four immuno-oncology programs, three of which focus on the adenosine-cancer axis to modulate an immune response. The Company's lead product candidate, CPI-444, is an oral, small molecule antagonist of the A2A receptor for adenosine, an immune checkpoint. Its other products include adenosine production inhibitor (a monoclonal anti-CD73 antibody); adenosine A2B antagonist, and interleukin-2 (IL-2)-inducible T cell kinase (ITK) inhibitors. As of September 30, 2016, the Company had not generated any revenue.
展开

Webull提供Corvus Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。